August 31, 2016
A key health ministry advisory is expected to discuss AbbVie’s Viekirax (ombitasvir + paritaprevir + ritonavir) on September 9 for an additional indication of genotype 2 hepatitis C without limiting the use to untreated patients, an informed source said. The...read more